DGIdb - F5 Gene Record

F5 2153 Druggable Genome

Alternate Names:

2153
COAGULATION FACTOR V
F5
FVL
PCCF
RPRGL1
THPH2
612309
3542
ENSG00000198734
OTTHUMG00000034595
P12259
COAGULATION FACTOR VA
FA5_HUMAN
Proaccelerin, labile factor
Activated protein C cofactor
Coagulation factor V light chain
Coagulation factor V heavy chain
PA159
T37510

Gene Info:

Target Class	Miscellaneous
Target Subclass	Enzyme cofactor
Target Main Class	Other
Gene Biotype	PROTEIN_CODING

(4 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME

Publications:

Straczek C et al., 2005, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration., Circulation
Wu O et al., 2005, Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study., Thromb Haemost
Cushman M et al., 2004, Estrogen plus progestin and risk of venous thrombosis., JAMA
Kemmeren JM et al., 2004, Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial., Blood
Oger E et al., 2003, Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial., Arterioscler Thromb Vasc Biol
Kemmeren JM et al., 2002, Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation., Blood Coagul Fibrinolysis
Legnani C et al., 2002, Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use., Eur Heart J
Herrington DM et al., 2002, Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease., Arterioscler Thromb Vasc Biol
Kemmeren JM et al., 2002, Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation., Thromb Haemost
Høibraaten E et al., 2001, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial., Br J Haematol
Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica
Spannagl M et al., 2000, Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?, Eur J Contracept Reprod Health Care
Martinelli I et al., 1999, Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis., Arterioscler Thromb Vasc Biol
Andersen BS et al., 1998, Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism., Thromb Haemost
Vandenbroucke JP et al., 1994, Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation., Lancet
Crawley JT et al., 2007, The central role of thrombin in hemostasis., J Thromb Haemost
Duggan C et al., 2003, Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer., J Clin Oncol
Abramson N et al., 2006, Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial., J Natl Cancer Inst

ESTRONE SODIUM SULFATE F5

Interaction Score: 61.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16301339 16113779 15467059 14551147 12869355 12138364 12069454 12067913 11859850 11703344 11532625 10943572 10073976 9459317 7968118

Sources:
PharmGKB
RIVAROXABAN F5

Interaction Score: 5.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
DROTRECOGIN ALFA (ACTIVATED) F5

Interaction Score: 3.86

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Coagulation factor V inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LUSUTROMBOPAG F5

Interaction Score: 2.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
AVATROMBOPAG F5

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ELTROMBOPAG F5

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
THROMBIN F5

Interaction Score: 0.64

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Trial Name ProFibrix B.V/

Novel drug target Established target

PMIDs:
17635715

Sources:
TdgClinicalTrial
TAMOXIFEN F5

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14512389 16818854

Sources:
PharmGKB FDA

Ensembl: ENSG00000198734
- Version: 101_38
Alternate Names:

F5 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P12259
- Version: 01-August-2011
Alternate Names:

FA5_HUMAN Uniprot Id

2153 Entrez Gene Id

ENSG00000198734 Ensembl Gene Id

Gene Info:

Target Main Class Other

Target Subclass Enzyme cofactor

Publications:
TdgClinicalTrial: P12259
- Version: January-2014
Alternate Names:

F5 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass Enzyme cofactor

Publications:

PharmGKB: F5

Version: 18-August-2020

Alternate Names:

PA159 PharmGKB ID

Gene Info:

Publications:

Abramson N et al., 2006, Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial., J Natl Cancer Inst

Duggan C et al., 2003, Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer., J Clin Oncol

Santamaría A et al., 2001, Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene., Haematologica

HingoraniCasas: ENSG00000198734
- Version: 31-May-2017
Alternate Names:

ENSG00000198734 Gene Symbol

F5 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: F5
- Version: chembl_23
Alternate Names:

F5 GENE_SYMBOL

Coagulation factor V UNIPROT

Coagulation factor V heavy chain UNIPROT

Gene Info:

Publications:
TTD: Coagulation factor Va
- Version: 2020.06.01
Alternate Names:

F5 TTD Gene Abbreviation

T37510 TTD Target ID

Gene Info:

Publications:
FDA: F5
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Mechanism of Interaction	Coagulation factor V inhibitor
Direct Interaction	yes

FA5_HUMAN	Uniprot Id
2153	Entrez Gene Id
ENSG00000198734	Ensembl Gene Id

F5	GENE_SYMBOL
Coagulation factor V	UNIPROT
Coagulation factor V heavy chain	UNIPROT

Trial Name	ProFibrix B.V/
Novel drug target	Established target

F5	TTD Gene Abbreviation
T37510	TTD Target ID

F5 Gene Record

F5 2153 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16301339 16113779 15467059 14551147 12869355 12138364 12069454 12067913 11859850 11703344 11532625 10943572 10073976 9459317 7968118

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Coagulation factor V inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: activator (activating)

Interaction Info: Trial Name ProFibrix B.V/ Novel drug target Established target

PMIDs: 17635715

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14512389 16818854

Sources: PharmGKB FDA

Ensembl: ENSG00000198734

Alternate Names: F5 Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

TEND: P12259

Alternate Names: FA5_HUMAN Uniprot Id 2153 Entrez Gene Id ENSG00000198734 Ensembl Gene Id

Gene Info: Target Main Class Other Target Subclass Enzyme cofactor

Publications:

TdgClinicalTrial: P12259

Alternate Names: F5 Gene Symbol

Gene Info: Target Class Miscellaneous Target Subclass Enzyme cofactor

Publications:

PharmGKB: F5

Alternate Names: PA159 PharmGKB ID

Gene Info:

HingoraniCasas: ENSG00000198734

Alternate Names: ENSG00000198734 Gene Symbol F5 Ensembl Id

Gene Info:

Gene Categories: DRUGGABLE GENOME

Publications:

ChemblInteractions: F5

Alternate Names: F5 GENE_SYMBOL Coagulation factor V UNIPROT Coagulation factor V heavy chain UNIPROT

Gene Info:

Publications:

TTD: Coagulation factor Va

Alternate Names: F5 TTD Gene Abbreviation T37510 TTD Target ID

Gene Info:

Publications:

FDA: F5

Alternate Names:

Gene Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
16301339 16113779 15467059 14551147 12869355 12138364 12069454 12067913 11859850 11703344 11532625 10943572 10073976 9459317 7968118

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Coagulation factor V inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

activator (activating)

Interaction Info:

Trial Name ProFibrix B.V/

Novel drug target Established target

PMIDs:
17635715

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
14512389 16818854

Sources:
PharmGKB FDA

Alternate Names:

F5 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

FA5_HUMAN Uniprot Id

2153 Entrez Gene Id

ENSG00000198734 Ensembl Gene Id

Gene Info:

Target Main Class Other

Target Subclass Enzyme cofactor

Alternate Names:

F5 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass Enzyme cofactor

Alternate Names:

PA159 PharmGKB ID

Alternate Names:

ENSG00000198734 Gene Symbol

F5 Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

F5 GENE_SYMBOL

Coagulation factor V UNIPROT

Coagulation factor V heavy chain UNIPROT

Alternate Names:

F5 TTD Gene Abbreviation

T37510 TTD Target ID